bioMIND‐A Novel Approach to Integrating Biomarkers in the Diagnostic Workup for Alzheimer's Disease

This study demonstrates that 17% of "real-world" patients referred to a tertiary memory clinic would be eligible for biomarker testing based solely on screening information provided by primary care. The biomarker-first approach is feasible and accurate, enabling earlier diagnostic clarification and personalized treatment opportunities for AD. This pathway could help shift care from late-stage symptom management to early intervention targeting disease pathology, improving outcomes and optimizing healthcare delivery.